1/3/2020 8:56:50 AM
Leap Therapeutics, BeiGene Announce Exclusive Option & License Agreement For DKN-01
11/14/2019 7:12:44 AM
Leap Therapeutics Q3 Loss Per Share $0.33 Vs Loss $0.55 Prior Year
8/9/2019 7:13:50 AM
Leap Therapeutics Q2 Net Loss $8.4 Mln Vs $7.4 Mln Last Year
8/6/2019 7:41:30 AM
Leap Presents Positive Clinical Results For The Combination Of DKN-01 Plus Keytruda
7/11/2019 8:04:20 AM
Leap Therapeutics Announces Common Stock Purchase Agreements For Up To $21 Mln With Lincoln Park Capital
5/15/2019 7:47:03 AM
Leap Therapeutics Q1 Net Loss $8.6 Mln Vs Loss $10.6 Mln Last Year
4/1/2019 4:09:07 PM
Leap Therapeutics Q4 Net Income To Shareholders $1.48 Mln Vs. Loss $6.59 Mln Last Year
1/31/2019 4:33:35 PM
Leap Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants
1/14/2019 7:11:52 AM
Leap Therapeutics Reports Investigator-Initiated Study Of DKN-01 In Patients With DKK1+ Advanced Prostate Cancer
12/14/2018 7:05:37 AM
Leap Therapeutics Presents Updated Data From DKN-01 Study In Biliary Tract Cancer
11/9/2018 7:07:36 AM
Leap Therapeutics Q3 Net Loss $6.6 Mln Vs Loss $6.8 Mln Last Year
8/8/2018 7:08:00 AM
Leap Therapeutics Q2 Net Loss $7.4 Mln Or $0.50/Shr